Drug intelligence / Profile preview

SP-017

Development stage: Preclinical
Lead developer: Sunny Pharmtech
Modality: Small Molecules
Administration: Intravenous

Overview

SP-017 is a small molecule anti-cancer therapeutic candidate being developed by Sunny Pharmtech for the treatment of Cutaneous T-Cell Lymphoma (CTCL) and Peripheral T-Cell Lymphoma (PTCL). Formulated as a high-potency (OEB5) injection, SP-017 is part of Sunny Pharmtech's pipeline of complex generics and value-added medicines. The program is currently in the early research and development (R&D) stage, leveraging the company's expertise in high-potency active pharmaceutical ingredients (HPAPIs) and specialized drug delivery systems. As a specialty pharmaceutical company and contract development and manufacturing organization (CDMO), Sunny Pharmtech focuses on the development of difficult-to-manufacture drug products.

Beyond the preview

Go deeper on SP-017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP-017.

Explore the full profile